Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11440
Title: Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.
Authors: Wai, Bryan;Kearney, Leighton G;Hare, David L;Ord, Michelle;Burrell, Louise M;Srivastava, Piyush M
Affiliation: Department of Cardiology, Austin Health, Heidelberg, VIC, Australia.
Issue Date: 14-Feb-2012
Citation: Cardiovascular Diabetology 2012; 11(): 14
Abstract: The prognostic benefits of beta-blockers (BB) in patients with systolic heart failure (SHF) are known but despite this, in patients with diabetes they are underutilized. The aim of this study was to assess the effect of beta-blockers (BB) on glycaemic control in patients with Type 2 Diabetes (T2DM) and systolic heart failure (SHF) stratified to beta-1 selective (Bisoprolol) vs. nonselective BB (Carvedilol).This observational, cohort study was conducted in patients with T2DM and SHF attending an Australian tertiary teaching hospital's heart failure services. The primary endpoint was glycaemic control measured by glycosylated haemoglobin (HbA1c) at initiation and top dose of BB. Secondary endpoints included microalbuminuria, changes in lipid profile and estimated glomerular filtration rate (eGFR).125 patients were assessed. Both groups were well matched for gender, NYHA class and use of guideline validated heart failure and diabetic medications. The mean treatment duration was 1.9 ± 1.1 years with carvedilol and 1.4 ± 1.0 years with bisoprolol (p = ns). The carvedilol group achieved a reduction in HbA1c (7.8 ± 0.21% to 7.3 ± 0.17%, p = 0.02) whereas the bisoprolol group showed no change in HbA1c (7.0 ± 0.20% to 6.9 ± 0.23%, p = 0.92). There was no significant difference in the change in HbA1c from baseline to peak BB dose in the carvedilol group compared to the bisoprolol group. There was a similar deterioration in eGFR, but no significant changes in lipid profile or microalbuminuria in both groups (p = ns).BB use did not worsen glycaemic control, lipid profile or albuminuria status in subjects with SHF and T2DM. Carvedilol significantly improved glycemic control in subjects with SHF and T2DM and this improvement was non significantly better than that obtained with bisoprolol. BB's should not be withheld from patients with T2DM and SHF.
Internal ID Number: 22330091
URI: http://ahro.austin.org.au/austinjspui/handle/1/11440
DOI: 10.1186/1475-2840-11-14
URL: http://www.ncbi.nlm.nih.gov/pubmed/22330091
Type: Journal Article
Subjects: Adrenergic beta-Antagonists.therapeutic use
Aged
Aged, 80 and over
Albuminuria.etiology
Biological Markers.blood
Bisoprolol.therapeutic use
Carbazoles.therapeutic use
Diabetes Mellitus, Type 2.blood.complications.drug therapy
Diabetic Nephropathies.etiology.physiopathology
Female
Glomerular Filtration Rate.drug effects
Heart Failure, Systolic.complications.drug therapy
Hemoglobin A, Glycosylated.metabolism
Hospitals, Teaching
Humans
Hypoglycemic Agents.therapeutic use
Lipids.blood
Male
Middle Aged
Propanolamines.therapeutic use
Prospective Studies
Time Factors
Treatment Outcome
Victoria
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
22330091.pdf240.27 kBAdobe PDFThumbnail
View/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.